NCT04539470View on ClinicalTrials.gov

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Acute Graft-versus-host Disease
Interventions
DRUG

Efmarodocokin Alfa

Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.

Trial Locations (8)

14263

Roswell Park Cancer Institute, Buffalo

33136

University of Miami Miller School of Medicine; Clinical Reseach Building, Miami

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

90095

Ronald Reagan UCLA Medical Center, Los Angeles

91010

City of Hope, Duarte

66160-7350

University of Kansas Med Ctr; Int med/Allgy/Immun/Rheum, Kansas City

02215

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT04539470 - Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter